Opinion|Videos|November 16, 2026

Brain Metastases Eligibility and Chemotherapy-Free Preferences

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, compares how 4 first-line trials in EGFR exon 20 insertion–mutated non–small cell lung cancer handled brain metastases.

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, compares how 4 first-line trials in EGFR exon 20 insertion–mutated non–small cell lung cancer handled brain metastases. PAPILLON and WU-KONG28 excluded active brain metastases, REZILIENT3 allowed untreated lesions smaller than 2 cm, and FURVENT allowed new asymptomatic brain metastases. She wants intracranial efficacy data for zipalertinib and firmonertinib, noting that zipalertinib has such data from second-line trials while she has not seen first-line data for firmonertinib. For patients with central nervous system disease, she may favor an oral agent whose trial enrolled such patients. Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, says patients fairly often decline chemotherapy after seeing a family member go through it. He stresses that toxicities from 25 or 30 years ago differ from today’s and that modern supportive care, including antiemetics, makes education important, yet some patients still refuse chemotherapy under any circumstances.


Related to this article